Surpass (Diclofenac/Calcium Carbonate) is commonly used to help with symptoms related to inflammatory or irritative states across several therapeutic domains, primarily in musculoskeletal and acute contexts.

This class of medication is generally used to treat symptoms of various forms of arthritis and other inflammatory conditions. It is relevant for managing conditions characterized by periods of heightened symptoms, such as Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, acute gout flare-ups, and pain from soft tissue injuries like strains, sprains, or tendonitis. The medication is also relevant for easing episodic discomfort, including acute migraine headaches and primary dysmenorrhea (menstrual cramps).

“It is applied in scenarios where additional management of discomfort is required, supporting the patient during difficult episodes by easing distress.”

This medication offers supportive relief and may help patients cope more steadily with symptom fluctuations, assisting with maintaining functional stability. The topical formulation is applied when appropriate for localized management of discomfort in specific peripheral joints.

Relevant Therapeutic Use: Musculoskeletal Pain and Stiffness It is commonly used to address symptom clusters that include joint pain, swelling, and stiffness, helping to ease the overall symptom burden in chronic and acute inflammatory conditions.

Regulatory References

1. NIH MedlinePlus overview of Diclofenac

Who Can and Cannot Use Surpass? Official Regulatory Information

Eligibility for Surpass (Diclofenac/Calcium Carbonate) is determined by official regulatory classifications that establish absolute prohibitions and conditional use requirements.

Populations for Whom Use is Contraindicated

Contraindications strictly prohibit the use of Surpass in several groups, primarily due to the NSAID component, Diclofenac:

• Patients with known hypersensitivity to diclofenac, aspirin, or any other Nonsteroidal Anti-Inflammatory Drug (NSAID).
• Patients with a history of NSAID-induced asthma, urticaria, or allergic-type reactions.
• Patients recovering from Coronary Artery Bypass Graft (CABG) surgery.
• Pregnant women starting at 30 weeks gestation and later (third trimester).
• Patients with active gastrointestinal ulceration, bleeding, or perforation.
• Patients with severe hepatic failure or severe renal failure (GFR less than 15 mL/ min/1.73 m^2).

Age-Related and Conditional Restrictions

Interactions with other medicines and products

Official regulatory information for Surpass, a combination product containing Diclofenac (NSAID) and Calcium Carbonate (Antacid), documents several interaction patterns.

Interaction Classifications and Restrictions

Documented Interaction Patterns

Co-administration with other medicines may result in three primary interaction patterns, as stated in regulatory sources:

• Additive Pharmacodynamic Risks: Combining Surpass with agents like Anticoagulants (e.g., Warfarin), SSRIs/SNRIs, or Corticosteroids increases the risk of bleeding or gastrointestinal adverse events. Furthermore, combination with Diuretics or ACE Inhibitors/ARBs may reduce their blood pressure-lowering effect and carry an additive risk of impaired renal function.
• Exposure Modification: Interactions occur with CYP2C9 Inhibitors (increasing Diclofenac plasma levels) and with CYP2C9 Inducers (decreasing plasma levels). Diclofenac may also reduce the renal clearance of co-administered agents like Lithium and Methotrexate, leading to increased plasma concentrations of these substances.
• Special Considerations: In elderly patients and those with compromised renal function, the severity of interaction-mediated adverse events, such as renal impairment or gastrointestinal bleeding, is noted as heightened.

The regulatory profile defines the interaction structure through these pharmacodynamic, pharmacokinetic, and physical chelation constraints, establishing specific prohibitions and administration intervals.

The drug's primary action is exerted by Diclofenac through the competitive inhibition of the Cyclooxygenase ( COX) enzymes, specifically both COX-1 and COX-2. This molecular binding prevents the conversion of Arachidonic Acid into pro-inflammatory prostaglandins ( PGE2), suppressing a critical step in the Arachidonic Acid Cascade. This interference decreases the chemical sensitization of peripheral nociceptors and modulates local fluid accumulation and vasodilation, contributing to the modulation of localized inflammatory responses. The second component, Calcium Carbonate, exerts a non-systemic, acid-neutralizing mechanism through rapid chemical buffering. By reacting with gastric hydrochloric acid ( HCl), it rapidly elevates the luminal pH. This functional action complements the systemic COX-1 inhibition by reducing the gastric acidity, thereby addressing the mechanism-dependent loss of protective prostaglandin production in the gastric mucosa.

How Surpass is Used: Administration Guidelines

Surpass (Diclofenac/Calcium Carbonate) is administered via two approved routes, with specific procedural rules for each form.

Administration Routes and Dosing Regimens

Contextual and Procedural Requirements

To ensure proper use, specific conditions surrounding the intake and application must be met. Oral tablets or capsules should be taken with or immediately after meals or milk; this requirement aligns with the product's design, which includes Calcium Carbonate, and is a condition for proper use. Certain oral forms, such as extended-release tablets, must be swallowed whole and must not be crushed, broken, or chewed.

For the topical cream, the treated area must be intact and should not be covered with occlusive dressings, exposed to external heat, or subjected to direct sunlight following application.

Use Patterns and Adjustments

Treatment must adhere to the principle of using the lowest effective dose for the shortest duration necessary. For specific populations, guidance advises caution and mandates adjustments: Older adults should be started on the lowest effective dosage, and patients with hepatic or renal impairment may require dose modification and continuous evaluation. These procedural steps and limitations define the administration protocol.

Research Evidence / Overview of Studies for Surpass

The research evidence for Surpass, which contains the NSAID Diclofenac and Calcium Carbonate, focuses on studies exploring symptom patterns related to inflammatory and irritative states. The structure of the evidence is primarily built on clinical trials known as Randomized Controlled Trials (RCTs), where the medicine is compared to an inactive substance (placebo) or another standard treatment. Research describes what was observed in the studies, providing context but not individual predictions.

Evidence for Use in Knee Osteoarthritis

Research exploring short-term symptom changes has mainly involved short-term and intermediate RCTs of the topical cream applied in studies examining patient-reported experiences. These trials examined outcomes related to physical discomfort and daily functioning. The populations studied were typically adults diagnosed with confirmed knee Osteoarthritis (OA).

Findings describe patterns observed in the studies, including measured changes in pain scores and changes in functional scale results over defined time intervals. The evidence profile was categorized as High concerning the research for the topical formulation in this specific joint condition. What remains uncertain is the full profile of long-term outcomes, particularly those that extend beyond three months of observation, which are not well characterized across the existing research base.

Evidence for Use in Acute Musculoskeletal Injuries

Research has explored the medicine in conditions involving periods of heightened symptoms, such as strains, sprains, and other soft-tissue injuries. Research primarily relies on short-term RCTs that assessed outcomes describing episodic or acute changes. The evidence structure was categorized as Moderate to High concerning the research design for the topical formulation in these acute localized conditions. However, follow-up durations were limited, typically only lasting one or two weeks, which means there is limited information on long-term outcomes related to full recovery or potential recurrence of the injury.

Areas of Research Uncertainty and Study Gaps

While evidence contributes to the broader evidence landscape, a primary research limitation is that the results apply only to the populations studied and may not translate reliably to all individuals. Follow-up durations were limited in many of the key efficacy studies. The existing research provides limited information for long-term outcomes, especially for consistency of observed outcomes over many months or years. Additionally, evidence quality varies across studies, depending on the formulation and the site of application.

Key Studies & References

1. Label: DICLOFENAC SODIUM 1.5% - diclofenac sodium topical solution (FDA/DailyMed)
2. Diclofenac Sodium Topical Gel, 1% (NSAID) - arthritis pain reliever (FDA/DailyMed)
3. Osteoarthritis Research Society International (OARSI) Guidelines for the management of knee osteoarthritis

Common questions about Surpass (FAQ)

Q: How quickly does Surpass start to work?

According to official product information, the primary active component, Diclofenac, typically begins to be absorbed rapidly. For oral forms, the medicine generally reaches its peak concentration in the bloodstream within a few hours.

Q: How long does the effect of Surpass last?

Studies and official information indicate that the duration of symptom improvement from the Diclofenac component has been described to last for up to eight hours in certain formulations. The length of time an effect is observed may vary depending on the specific product type.

Q: Is Surpass safe to take long-term?

Regulatory documents state that the risks of serious adverse events, particularly cardiovascular and gastrointestinal issues, may increase with longer durations of use. Treatment is guided by the principle of the lowest effective dose for the shortest duration necessary. Regulatory guidance notes that the need for continued long-term use is subject to periodic re-evaluation.

Q: Is there a generic version of Surpass available?

The specific combination product containing Diclofenac and Calcium Carbonate has approved generic versions available from several different manufacturers.

Q: Can Surpass be used while breastfeeding?

Authoritative sources indicate that levels of the active component (Diclofenac) transferred into breast milk are low, and the drug is often considered for use during breastfeeding. Decisions on use during lactation are based on individual assessment.

Q: Does Surpass affect my ability to drive or operate machinery?

Official documents note that certain side effects, such as dizziness or vertigo, may be experienced. If these effects occur, they could potentially impair the ability to perform tasks requiring alertness, such as driving or operating complex machinery.

Q: What if I'm already taking medicine for high blood pressure? Can I still use Surpass?

Regulatory information advises that this medicine can potentially worsen pre-existing high blood pressure. Furthermore, it may reduce the effectiveness of certain blood pressure medications, such as diuretics or ACE inhibitors, so use under these conditions is managed with caution.

Q: Is Surpass used to treat chronic conditions?

The medicine is officially indicated for the management of signs and symptoms associated with chronic inflammatory conditions. These include specific forms of osteoarthritis and rheumatoid arthritis, which are characterized by persistent or long-lasting symptoms.

Q: What are the long-term effects of Surpass use?

Official documentation advises that the risks of serious adverse events, including gastrointestinal bleeding and cardiovascular thrombotic events, increase with the duration of use. Official guidance often refers to the principle of using the medicine for the shortest duration necessary.

Q: Do the side effects of Surpass usually go away over time?

Official patient information suggests that common, non-serious side effects, such as temporary dizziness, may lessen as the body adjusts to the medication over time. If a side effect persists or is of concern, consulting a healthcare professional is generally recommended.

Q: Is Surpass suitable for people with liver disease?

Official regulatory information advises that caution should be exercised when the medicine is used in the presence of non-severe liver disease, as slower removal of the medicine from the body may increase its effects. Severe liver impairment remains an official contraindication for use.

Q: Can people with diabetes use Surpass?

Patients with risk factors for cardiovascular events, including a history of diabetes, may require a careful risk-benefit consideration for treatment due to the increased cardiovascular risk profile noted in regulatory documents.

Q: Are there any age restrictions for using Surpass?

The safety and effectiveness of the medicine have not been established for children and adolescents under 18 years of age. Official indication typically applies to adults aged 18 and older.

Q: Does Surpass cause weight gain or weight loss?

Regulatory documents note that fluid retention and edema (swelling due to fluid accumulation) have been observed in some patients taking NSAIDs, the drug class of the active component. This fluid retention may be associated with weight increase.

Q: Is it okay to drink alcohol while taking Surpass?

Official warnings strongly advise against the use of alcohol while taking this medicine. Alcohol consumption can increase the risk of serious gastrointestinal adverse events, such as bleeding and ulcers, which are already a documented risk of this drug class.

Q: What should I do if Surpass makes me feel nauseous?

Nausea is a common gastrointestinal side effect. Official patient information often suggests taking the oral form of the medicine with food or milk to help mitigate this type of common gastrointestinal discomfort.

Q: Does Surpass interact with common over-the-counter pain relievers?

Official guidance advises against combining this medicine with other non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen or naproxen, due to the increased risk of side effects. However, it can generally be used with non-NSAID pain relievers like paracetamol (acetaminophen).

Q: Can Surpass be taken with vitamins or herbal supplements?

Official sources note that many complementary medicines, herbal remedies, and supplements are not fully tested for interactions with prescription drugs. Consultation with a healthcare professional before concurrent use is necessary to evaluate potential risks, as comprehensive interaction data may be lacking.

Q: How is Surpass stored after the package is opened?

The storage requirements often depend on the specific formulation. For the topical cream or gel, product information may advise that the medication should be used or discarded after a specific, limited number of days following the initial opening of the tube.

Q: Is Surpass addictive?

The medicine is classified as a non-narcotic, non-steroidal anti-inflammatory drug (NSAID). Its chemical structure and mechanism of action do not involve the pathways associated with dependency or addiction.

Q: Why do some people say Surpass gives them an upset stomach?

Gastrointestinal upset is a common side effect associated with the Diclofenac component's mechanism of action. Diclofenac inhibits protective prostaglandins in the stomach lining. The medicine's formulation includes Calcium Carbonate, which is designed to help reduce stomach acidity and mitigate this effect.

Q: Are there any lab tests needed before or during the use of Surpass?

Official prescribing information advises that certain laboratory tests and clinical monitoring may be required during treatment. These checks often include evaluations of blood pressure, renal (kidney) function, and hepatic (liver) function.

Q: Is it normal to feel tired when starting Surpass?

The adverse event profile of the Diclofenac component includes documented reports of tiredness or fatigue. If this symptom is severe or persistent, it is appropriate to consult a healthcare professional.

Q: What kind of monitoring is required while on Surpass?

Official prescribing information advises that certain clinical monitoring procedures are recommended. These include checks of blood pressure, and evaluations of renal (kidney) and hepatic (liver) function to ensure the medicine is being tolerated correctly.

Q: Does Surpass make you more sensitive to the sun?

Regulatory documents note that the medicine may cause increased sensitivity of the skin to sunlight, which is a reaction known as photosensitivity. Official guidance often describes preventive measures, such as limiting sun exposure or using sun protection, when using medications with this risk.

Q: Does Surpass affect my mood?

The adverse event profile includes rare reports of psychiatric or mood-related effects. These may include instances of anxiety, depression, or irritability, as documented in official prescribing information.

How to Store and Dispose of Surpass (Diclofenac/Calcium Carbonate)

Surpass must be stored at Controlled Room Temperature, specifically between 68 F to 77 F (20 C to 25 C). The medication must be kept in its original container, and the container should be tightly closed to protect the contents from moisture. Do not freeze the product, and avoid storing it in high-moisture areas like the bathroom.

Child Safety and Disposal

Official labeling requires that Surpass be stored out of the reach of children. For disposal, unused or expired medicine must not be flushed down the toilet or poured into a drain. Instead, regulatory guidance advises using a medicine take-back program or mixing the product with an unappealing substance, sealing it, and placing it in household trash.